Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATG7 | O95352 | 10/20 | 0.47 |
| ▸ | NAE1 | Q13564 | 4/20 | 0.41 |
| ▸ | UBA3 | Q8TBC4 | 4/20 | 0.41 |
| ▸ | UBA6 | A0AVT1 | 1/20 | 0.40 |
| ▸ | UBA7 | P41226 | 1/20 | 0.40 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5318335 | 1.00 | ATG7 (0.47) | ATG7NAE1UBA3UBA6UBA7 | |
| SCHEMBL19991760 | 0.87 | DNPH1 (0.48) | ATG7NAE1UBA3UBA6UBA7 | |
| SCHEMBL1796834 | 0.85 | HIF1A (0.36) | — | |
| SCHEMBL23080288 | 0.82 | ATG7 (0.46) | ATG7NAE1UBA3UBA6UBA7 | |
| SCHEMBL12567198 | 0.81 | ATG7 (0.46) | ATG7NAE1UBA3UBA6UBA7 | |
| SCHEMBL17889811 | 0.79 | ATG7 (0.67) | ATG7NAE1UBA3UBA6UBA7 | |
| SCHEMBL1795396 | 0.79 | ATG7 (0.67) | ATG7NAE1UBA3UBA6UBA7 | |
| SCHEMBL18630444 | 0.78 | ATG7 (0.47) | ATG7NAE1UBA3UBA6UBA7 | |
| SCHEMBL1800449 | 0.77 | RXFP1 (0.61) | ATG7NAE1UBA3UBA6UBA7 | |
| SCHEMBL23080273 | 0.77 | CA2 (0.55) | ATG7NAE1UBA3CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210070798-A1 | Inhibitors of E1 activating enzymes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-11 | — | — | US | disclosed |
| US-20180086785-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | MILLENNIUM PHARMACEUTICALS, INC. | 2018-03-29 | — | — | US | disclosed |
| US-20180086785-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | MILLENNIUM PHARMACEUTICALS, INC. | 2018-03-29 | — | — | US | disclosed |
| US-20180086785-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | MILLENNIUM PHARMACEUTICALS, INC. | 2018-03-29 | — | — | US | disclosed |
| US-20170073367-A9 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | MILLENIUM PHARMACEUTICALS, INC. | 2017-03-16 | — | — | US | disclosed |
| US-20170073367-A9 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | MILLENIUM PHARMACEUTICALS, INC. | 2017-03-16 | — | — | US | disclosed |
| US-20170073367-A9 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | MILLENIUM PHARMACEUTICALS, INC. | 2017-03-16 | — | — | US | disclosed |
| US-20160194348-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | MILLENNIUM PHARM INC (US) | 2016-07-07 | — | — | US | disclosed |
| US-20160194348-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | MILLENNIUM PHARM INC (US) | 2016-07-07 | — | — | US | disclosed |
| US-20160194348-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | MILLENNIUM PHARM INC (US) | 2016-07-07 | — | — | US | disclosed |
| EP-1848718-B1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARM INC (US) | 2012-08-01 | — | — | EP | disclosed |
| US-20110136834-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | US | disclosed |
| US-20110136834-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | US | disclosed |
| US-20110136834-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | US | disclosed |
| US-7951810-B2 | Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-7951810-B2 | Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-7951810-B2 | Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| EP-1848718-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-10-31 | — | — | EP | disclosed |
| US-20060189636-A1 | Inhibitors of E1 activating enzymes | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-08-24 | — | — | US | disclosed |
| WO-2006084281-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086785-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | TYMP, TYMS, PPA1 | ATG7 2417/4885NAE1 257/4885UBA3 235/4885 |
| US-20170073367-A9 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | TYMP, TYMS, PPA1 | ATG7 2417/4885NAE1 257/4885UBA3 235/4885 |
| US-20110136834-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | ECE1, RNASE1, RCE1 | ATG7 1114/4885NAE1 41/4885UBA3 12/4885 |
| US-20160194348-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | TYMP, TYMS, PPA1 | ATG7 2417/4885NAE1 257/4885UBA3 235/4885 |
| US-20210070798-A1 | Inhibitors of E1 activating enzymes | ECE1, RNASE1, RCE1 | ATG7 1114/4885NAE1 41/4885UBA3 12/4885 |
| US-20060189636-A1 | Inhibitors of E1 activating enzymes | ECE1, RNASE1, RCE1 | ATG7 1114/4885NAE1 41/4885UBA3 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.